SG11202002594PA - Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress - Google Patents
Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stressInfo
- Publication number
- SG11202002594PA SG11202002594PA SG11202002594PA SG11202002594PA SG11202002594PA SG 11202002594P A SG11202002594P A SG 11202002594PA SG 11202002594P A SG11202002594P A SG 11202002594PA SG 11202002594P A SG11202002594P A SG 11202002594PA SG 11202002594P A SG11202002594P A SG 11202002594PA
- Authority
- SG
- Singapore
- Prior art keywords
- dpp3
- epitopes
- diseases
- prevention
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17198420 | 2017-10-25 | ||
| PCT/EP2018/079197 WO2019081595A2 (fr) | 2017-10-25 | 2018-10-24 | Liant dpp3 dirigé vers et se liant à des épitopes dpp3 spécifiques et son utilisation dans la prévention ou le traitement de maladies/états aigus associés au stress oxydatif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002594PA true SG11202002594PA (en) | 2020-04-29 |
Family
ID=60186108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002594PA SG11202002594PA (en) | 2017-10-25 | 2018-10-24 | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11530276B2 (fr) |
| EP (1) | EP3700937A2 (fr) |
| JP (2) | JP7424972B2 (fr) |
| KR (1) | KR20200083509A (fr) |
| CN (1) | CN111542548A (fr) |
| AU (1) | AU2018356441A1 (fr) |
| BR (1) | BR112020006563A2 (fr) |
| CA (1) | CA3080251A1 (fr) |
| IL (1) | IL274009A (fr) |
| MX (1) | MX2020004271A (fr) |
| SG (1) | SG11202002594PA (fr) |
| WO (1) | WO2019081595A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115769076A (zh) | 2020-03-16 | 2023-03-07 | 4Teen4制药有限公司 | 感染冠状病毒的患者中的dpp3 |
| EP3922993A1 (fr) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 chez des patients infectés par le coronavirus |
| WO2024126793A1 (fr) | 2022-12-15 | 2024-06-20 | 4TEEN4 Pharmaceuticals GmbH | Inhibiteur de dpp3 pour l'amélioration de la fonction pulmonaire chez des patients gravement malades |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6188884A (ja) | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1992020791A1 (fr) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methode de production de chainons de paires de liaison specifique |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0746609A4 (fr) | 1991-12-17 | 1997-12-17 | Genpharm Int | Animaux transgeniques non humains capables de produire des anticorps heterologues |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2001016334A2 (fr) | 1999-09-01 | 2001-03-08 | Incyte Genomics, Inc. | Enzymes hydrolytiques humains |
| IL160289A0 (en) | 2001-08-30 | 2004-07-25 | Biorexis Pharmaceutical Corp | Modified transferrin fusion proteins |
| EP2298278B1 (fr) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prévention et réduction de perte sanguine et la réponse inflammatoire |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2005106486A2 (fr) | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3) |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| JP2006230318A (ja) | 2005-02-25 | 2006-09-07 | Maruishi Pharmaceutical Co Ltd | 関節リウマチの診断方法 |
| WO2007117444A2 (fr) | 2006-03-31 | 2007-10-18 | Yinghe Hu | Détection de protéines au moyen d'aptamères |
| EP2030025A2 (fr) | 2006-06-07 | 2009-03-04 | Tethys Bioscience, Inc. | Marqueurs associés à des événements artério-vasculaires et procédés d'utilisation de ces marqueurs |
| ATE527353T1 (de) | 2007-12-19 | 2011-10-15 | Affibody Ab | Pdgf-bindendes polypeptid aus protein a |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| US8715928B2 (en) * | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
| WO2010113096A1 (fr) * | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Méthodes pour prévoir l'évolution clinique de la sclérose en plaque et la traiter |
| BR112012004314A2 (pt) | 2009-08-27 | 2016-11-29 | Covagen Ag | compostos de ligação a il-17 e usos medicinais desses compostos |
| CA2778871C (fr) | 2009-12-14 | 2017-08-01 | Scil Proteins Gmbh | Proteines d'ubiquitine modifiee possedant une activite de liaison specifique pour l'extradomaine b de la fibronectine |
| WO2011154420A2 (fr) | 2010-06-08 | 2011-12-15 | Pieris Ag | Mutéines de lipocaline des larmes se liant à il-4 r alpha |
| CN105228633A (zh) | 2013-01-28 | 2016-01-06 | 新天然替代品公司 | 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物 |
| CN104946646B (zh) * | 2014-03-25 | 2020-03-31 | 中国医学科学院基础医学研究所 | 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用 |
| JP2019520550A (ja) * | 2016-04-21 | 2019-07-18 | スフィンゴテック セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ３の定量方法および治療方法 |
-
2018
- 2018-10-24 CN CN201880069013.0A patent/CN111542548A/zh active Pending
- 2018-10-24 KR KR1020207014841A patent/KR20200083509A/ko not_active Application Discontinuation
- 2018-10-24 SG SG11202002594PA patent/SG11202002594PA/en unknown
- 2018-10-24 MX MX2020004271A patent/MX2020004271A/es unknown
- 2018-10-24 JP JP2020523261A patent/JP7424972B2/ja active Active
- 2018-10-24 WO PCT/EP2018/079197 patent/WO2019081595A2/fr unknown
- 2018-10-24 US US16/758,881 patent/US11530276B2/en active Active
- 2018-10-24 CA CA3080251A patent/CA3080251A1/fr active Pending
- 2018-10-24 BR BR112020006563-3A patent/BR112020006563A2/pt unknown
- 2018-10-24 EP EP18795970.5A patent/EP3700937A2/fr active Pending
- 2018-10-24 AU AU2018356441A patent/AU2018356441A1/en active Pending
-
2020
- 2020-04-16 IL IL274009A patent/IL274009A/en unknown
-
2022
- 2022-11-10 US US17/984,611 patent/US20230295344A1/en active Pending
-
2024
- 2024-01-18 JP JP2024006108A patent/JP2024041975A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019081595A2 (fr) | 2019-05-02 |
| JP2024041975A (ja) | 2024-03-27 |
| AU2018356441A1 (en) | 2020-04-16 |
| IL274009A (en) | 2020-05-31 |
| CN111542548A (zh) | 2020-08-14 |
| US11530276B2 (en) | 2022-12-20 |
| US20230295344A1 (en) | 2023-09-21 |
| US20210206876A1 (en) | 2021-07-08 |
| JP2021500376A (ja) | 2021-01-07 |
| MX2020004271A (es) | 2020-07-29 |
| RU2020116450A3 (fr) | 2021-12-21 |
| BR112020006563A2 (pt) | 2020-10-13 |
| JP7424972B2 (ja) | 2024-01-30 |
| RU2020116450A (ru) | 2021-11-25 |
| CA3080251A1 (fr) | 2019-05-02 |
| KR20200083509A (ko) | 2020-07-08 |
| EP3700937A2 (fr) | 2020-09-02 |
| WO2019081595A4 (fr) | 2019-09-06 |
| WO2019081595A3 (fr) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277551A (en) | Tri-specific binding molecules against cancer and their uses | |
| IL279752A (en) | Polycyclic compounds and their use in the treatment of immune disorders | |
| IL272524A (en) | CLEC9A binding factors and their use | |
| SI3097122T1 (sl) | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo | |
| HK1245287A1 (zh) | IL13RAα2結合劑和其在癌症治療中的用途 | |
| PT3583129T (pt) | Moléculas de ligação a cd70 e seus métodos de uso | |
| EP3565812C0 (fr) | Composés se liant à la tubuline et leur usage thérapeutique | |
| IL271503A (en) | Preparations and treatments for sleep disorders | |
| IL274009A (en) | DDP3 binding targets and binds to DDP3-specific epitopes and their use to prevent or treat diseases/acute cases associated with acidosis | |
| EP3262075C0 (fr) | Nouvel anticorps se liant à la tfpi et composition le comprenant | |
| IL276063A (en) | Medicinal compounds that bind to lag3 and pd1 | |
| IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
| IL272414A (en) | Use of gaboksadol in the treatment of diabetes and related conditions | |
| IL269318A (en) | Antibodies to human erythroperone and uses thereof | |
| SG11201704486TA (en) | Improvements in and relating to the treatment of matrices and/or the contents of matrices | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| EP3110453A4 (fr) | Peptides tmem100 et variants de ceux-ci et leur utilisation dans le traitement ou la prévention de maladies ou d'états pathologiques | |
| EP3636712C0 (fr) | Composition de caoutchouc fluoré et produit réticulé en caoutchouc fluoré | |
| PL3728444T3 (pl) | Spoiwa i powiązane produkty | |
| IL261033A (en) | Human antibodies and tensin-binding fragments | |
| GB201707336D0 (en) | Improvements in and relating to spinners | |
| GB201721668D0 (en) | Extract and use thereof | |
| SI3568146T1 (sl) | Rastlinski izvleček za preprečevanje in zdravljenje izpadanja las | |
| GB201710038D0 (en) | Supplication prior to and after eating | |
| GB201714668D0 (en) | Improvements in or relating to heating devices and methods |